4 documents found, page 1 of 1
AT LAST! It was not a progression!
Paulinetti Camara, Raquel; Lopes, Kelly; Barbosa, Miguel; Sucena, Inês; Simão, Carla; Mota, Paulo; Matias, Dina; Sequeira, Telma; Almodovar, TeresaIntroduction: Nivolumab is approved in Portugal for non-small cell metastatic lung cancer, as one of the indications, after progressing on chemotherapy. As an immune checkpoint inhibitor (ICI) immune-related adverse events (irAE) are possible reactions. Case report: A 64-year-old man with stage III lung adenocarcinoma who progressed after chemoradiotherapy and first line metastatic chemotherapy started nivoluma...
Portuguese Consensus Recommendations for Next-Generation Sequencing of Lung Can...
R. Teixeira, Manuel; Oliveira, Júlio; Borralho, Paula; O. Fernandes, Maria Gabriela; Almodovar, Teresa; Fernandes, Isabel; Macedo, DanielaNext-generation sequencing (NGS) has been implemented in clinical oncology for diagnosis, prognosis, and therapeutic guidance. Among the various NGS applications in molecular oncology, we focused on the following topics: laboratory standards for targeted gene panels (somatic mutations) and therapeutic guidance based on NGS of lung cancer and rare cancers, namely sarcomas and cancers of unknown primary. Multiple...
UNUSUAL BEHAVIOUR OF A LUNG INFLAMMATORY MYOFIBROBLASTIC TUMOUR
Cabral, Daniel; Rodrigues, Cristina; Almodovar, Teresa; Ribeiro, Analisa; Mota, Leonor; Félix, FranciscoInflammatory myofibroblastic tumours (IMTs) are rare lesions. We report a case of a 55 year-old male, admitted with a pneumonia. Further investigation revealed a left lower lobe mass and enlarged mediastinal lymph nodes. Cytology of the bronchoalveolar lavage suggested a squamous cell carcinoma. He received four cycles of chemotherapy followed by a left lower lobectomy. Pathological analysis was compatible with...